Outcomes Data For Sanofi/Regeneron’s Praluent May Land In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analyses from the events-driven trial of the PCSK9 inhibitor may be available next year, helping to pave the way for broader labeling.